NCT07396766 (BREASTChoice) is a NA clinical trial of Baseline Questionnaire in Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Who is sponsoring NCT07396766?

NCT07396766 is sponsored by UNC Lineberger Comprehensive Cancer Center.

What drugs are being tested in NCT07396766?

Interventions in NCT07396766: Baseline Questionnaire, Semi structured Interview, Post Survey.

What condition does NCT07396766 study?

NCT07396766 studies Breast Cancer, Breast Neoplasms.

Is NCT07396766 still recruiting?

NCT07396766 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT07396766: BREASTChoice

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dissemination of BREASTChoice AIM1-B

Recruiting now NA Last updated 9 February 2026

What this trial tests

NA trial testing Baseline Questionnaire in Breast Cancer in 20 participants. Currently enrolling.

Timeline

1 October 2025

Primary endpoint
20 January 2029

20 January 2029

Quick facts

Lead sponsor	UNC Lineberger Comprehensive Cancer Center
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	20
Start date	1 October 2025
Primary completion	20 January 2029
Estimated completion	20 January 2029
Sites	1 location across United States

Drugs / interventions tested

Baseline Questionnaire
Semi structured Interview
Post Survey

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Breast Neoplasms — all drugs for Breast Neoplasms →

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Breast Cancer or Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their thoughts and reactions. Interviews will include open-ended questions about the content and format of the decision aid, with follow-up prompts to gather feedback on design elements (length, order, graphics), comprehension, ease of use, acceptance, and engagement with the tool. Knowledge will be measured using the Decision Quality Instrument before and after using the tool. Results will be analyzed to develop recommendations for the final version of the tool.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other UNC Lineberger Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06656936 — The PharmFIT Study · NA · not yet recruiting
NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07396766 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07396766.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing